Elements of cancer immunity and the cancer-immune set point
Autor: | Daniel S. Chen, Ira Mellman |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
animal diseases medicine.medical_treatment T-Lymphocytes chemical and pharmacologic phenomena Context (language use) Biology Bioinformatics Epigenesis Genetic 03 medical and health sciences Therapeutic approach 0302 clinical medicine Immune system Immunity Neoplasms medicine Animals Humans Set (psychology) Inflammation Multidisciplinary Genome Human Cancer Immunotherapy biochemical phenomena metabolism and nutrition medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Immunology biology.protein bacteria Tumor Escape Antibody Immunologic Memory |
Zdroj: | Nature. 541(7637) |
ISSN: | 1476-4687 |
Popis: | Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual. |
Databáze: | OpenAIRE |
Externí odkaz: |